VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2020 | ETOP/IFCT 4-12 STIMULI updates from ESMO 2020

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, discusses the results from the ETOP/IFCT 4-12 STIMULI trial (NCT02046733). The trial investigated the consolidation of ipilimumab and nivolumab in limited-stage small-cell lung cancer compared with standard chemo-radiotherapy treatment alone and found no progression-free survival or overall survival advantage. Prof. Popat proposes that this may be due to high discontinuation rates resulting from the incidence of Grade 3+ immune-related adverse events. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter